Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Radient Pharmaceuticals’ Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presenta…

December 5, 2011 By Bio-Medicine.Org

TUSTIN, Calif., Dec. 5, 2011 /PRNewswire/ — Radient
Pharmaceuticals Corporation  (OTCQX:RXPC) (OTCPK:RXPC),
developer and marketer of the Onko-Sure® In Vitro
Diagnostic
(IVD) cancer test, announced today that the two
abstracts it submitted to the 2012 Gastrointestinal Cancers
Symposium (ASCO Conference) were accepted for presentation from
among 730 abstracts submitted. The meeting will be held on January
19-21, 2012 at the Moscone West Building in San Francisco,
California. Dr. Afsaneh Motamed-Khorasani, the Director of Oncology
at Radient, will be presenting the data.

These two abstracts were the results of a collaborative study in
the United States that compared the combined use of Onko-Sure®
with carcinoembryonic antigen (CEA), the routine blood biomarker
for colorectal cancer (CRC), and CEA alone. The clinical trial
included a total of 564 subjects. Radient’s proprietary
Onko-Sure® cancer blood test combined with CEA test were more
effective for the detection of colorectal cancer compared to using
CEA test alone (an increase of 56% in the test sensitivity).
Furthermore, the combined usage of Onko-Sure® and CEA in
monitoring CRC recurrence showed a significant clinical advantage
in terms of sensitivity (an increase of 35% in the test
sensitivity). This was in line with a previous UK study published
in peer reviewed journals in 2010.

Onko-Sure® has already been cleared by the US FDA for the
monitoring of the treatment and recurrence in CRC. “We believe that
Onko-Sure® provides a platform technology that is highly
effective in the monitoring of colorectal cancer. Should an in
vitro diagnostics test increase early detection of CRC recurrence
when used adjunctively with other available diagnostic markers, the
number of annual deaths due to CRC recurrence could be reduced. An
increase in early detection has the potential to lead to an
increased survival rate of patients,” stated Radient
Pharmaceuticals C

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech